1
|
Fitoussi R, Gascon P, Denis D, Mathis T, Tieulé N, Schneider-Rouhaud C, Attia R, David T, Stolowy N. Epidemiological, Clinical, and Therapeutic Profile of Uveitis in Multiple Sclerosis: A Multicenter Study. Ocul Immunol Inflamm 2024:1-5. [PMID: 38602890 DOI: 10.1080/09273948.2024.2337839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 03/27/2024] [Indexed: 04/13/2024]
Abstract
INTRODUCTION Uveitis may occur during approximately 1-3% of MS patients, corresponding to 10 times higher than in the general population. The development of uveitis is not currently considered as an inflammatory relapse of MS. There are no clinical guidelines for treating. MS with concomitant uveitis requiring systemic treatment. PURPOSES To analyze clinical and therapeutic characteristics of uveitis in patients with MS and the impact of MS treatment on the progression of uveitis. MATERIALS & METHODS We conducted a retrospective, observational, multicenter study in France about 54 patients. RESULTS The form of MS most frequently associated with uveitis in our study was the relapsing-remitting form (85%). The mean time of onset of uveitis was 15 months before the diagnosis of MS. The most frequent form of uveitis was bilateral panuveitis (43%), non-granulomatous (61%), synechial (52%) and non-hypertonic (93%) with progressive onset (65%) and chronic course (66%). CONCLUSION MS-associated uveitis occurs most frequently before the diagnosis of relapsing-remitting MS in the form of panuveitis or intermediate uveitis, which is mildly inflammatory and whose main complications are macular edema, cataract and venous vasculitis. Despite their chronicity, these uveitis cases have a good visual prognosis and teriflunomide appears to have a positive effect on progression.
Collapse
Affiliation(s)
- R Fitoussi
- Department of Ophthalmology, Hopital Timone, Marseille, France
| | - P Gascon
- Department of Ophthalmology, Hopital Timone, Marseille, France
| | - D Denis
- Department of Ophthalmology, Hopital Timone, Marseille, France
| | - T Mathis
- Department of Ophthalmology, Hopital Croix-Rousse, Lyon, France
| | - N Tieulé
- Department of Ophthalmology, Hopital Pasteur, Nice, France
| | | | - R Attia
- Department of Ophthalmology, Hopital Timone, Marseille, France
| | - T David
- Department of Ophthalmology, Hopital Timone, Marseille, France
| | - N Stolowy
- Department of Ophthalmology, Hopital Timone, Marseille, France
| |
Collapse
|
2
|
Arnould T, Dalmas F, Denis D, Gascon P, Comet A. Communication artérioveineuse rétinienne : à propos de deux cas. J Fr Ophtalmol 2022; 45:480-482. [DOI: 10.1016/j.jfo.2021.10.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Revised: 10/20/2021] [Accepted: 10/24/2021] [Indexed: 11/26/2022]
|
3
|
Mairot K, Sahakian N, Salgues B, Levy N, Gascon P, Denis D. Somatostatin receptor PET/CT scan as a helpful diagnostic tool for optic nerve sheath meningioma. J Fr Ophtalmol 2021; 44:e619-e621. [PMID: 34229893 DOI: 10.1016/j.jfo.2021.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 01/04/2021] [Accepted: 01/04/2021] [Indexed: 11/24/2022]
Affiliation(s)
- K Mairot
- Service d'ophtalmologie, centre hospitalier universitaire de l'hôpital Nord, Chemin des Bourrely, 13015 Marseille, France.
| | - N Sahakian
- Médecine nucléaire, centre hospitalier universitaire de l'hôpital Nord, Chemin des Bourrely, 13015 Marseille, France
| | - B Salgues
- Médecine nucléaire, groupe hospitalier Pitié-Salpêtrière-Charles Foix, Sorbonne université, Paris, France
| | - N Levy
- Service d'ophtalmologie, centre hospitalier universitaire de l'hôpital Nord, Chemin des Bourrely, 13015 Marseille, France
| | - P Gascon
- Service d'ophtalmologie, centre hospitalier universitaire de l'hôpital Nord, Chemin des Bourrely, 13015 Marseille, France
| | - D Denis
- Service d'ophtalmologie, centre hospitalier universitaire de l'hôpital Nord, Chemin des Bourrely, 13015 Marseille, France
| |
Collapse
|
4
|
Donnadieu B, Comet A, Gascon P, Ramtohul P, Callet M, Denis D, Matonti F. Scleral fixated intraocular lens by a modified technique: Methods and results. J Fr Ophtalmol 2020; 43:312-318. [PMID: 32115270 DOI: 10.1016/j.jfo.2019.08.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 08/02/2019] [Accepted: 08/20/2019] [Indexed: 11/16/2022]
Abstract
PURPOSE A certain number of conditions can result in compromised anterior and/or posterior capsular integrity. Several surgical options have been employed for repositioning dislocated intraocular lenses in the absence of adequate capsular support. The purpose of this study is to assess the functional outcomes and complication profile of a modified surgical technique for replacing dislocated intraocular lenses. MATERIAL AND METHODS All patients who had undergone the modified surgical procedure for dislocated intraocular lenses between 2012 and 2017 were retrospectively reviewed for visual outcomes and complications. Patient demographic characteristics, pre- and postoperative visual acuity, surgical indications, refractive outcomes, intraocular pressure and postoperative complications were recorded and analysed at baseline and at six months, which was the conclusion of the study. We also present our modified surgical technique. RESULTS Sixty-eight eyes of sixty-eight patients (74% male) were included. Mean age at surgery was 58 years (range 4-89 years). Mean best-corrected visual acuity increased significantly from 0.80 (SD±0.2) LogMar to 0.40 (SD±0.1) LogMar (P<0.005). Median astigmatic error at the conclusion of follow-up remained stable. There were no intraoperative complications and a low postoperative complication rate (10.2%), mainly related to the surgical context. CONCLUSION Sutureless intrascleral fixation of dislocated intraocular lenses is an option in case of deficient capsular support. Visual outcomes and complication rates are comparable to other case series.
Collapse
Affiliation(s)
- B Donnadieu
- Assistance Publique-Hôpitaux de Marseille, centre hospitalier universitaire NORD, chemin des Bourrely, 13015 Marseille, France.
| | - A Comet
- Assistance Publique-Hôpitaux de Marseille, centre hospitalier universitaire NORD, chemin des Bourrely, 13015 Marseille, France
| | - P Gascon
- Assistance Publique-Hôpitaux de Marseille, centre hospitalier universitaire NORD, chemin des Bourrely, 13015 Marseille, France; Institut de neurosciences de la Timone, CNRS, Aix-Marseille Université, UMR 7289, Campus Santé Timone, 27, boulevard Jean-Moulin, 13005 Marseille, France
| | - P Ramtohul
- Assistance Publique-Hôpitaux de Marseille, centre hospitalier universitaire NORD, chemin des Bourrely, 13015 Marseille, France
| | - M Callet
- Assistance Publique-Hôpitaux de Marseille, centre hospitalier universitaire NORD, chemin des Bourrely, 13015 Marseille, France
| | - D Denis
- Assistance Publique-Hôpitaux de Marseille, centre hospitalier universitaire NORD, chemin des Bourrely, 13015 Marseille, France
| | - F Matonti
- Institut de neurosciences de la Timone, CNRS, Aix-Marseille Université, UMR 7289, Campus Santé Timone, 27, boulevard Jean-Moulin, 13005 Marseille, France; Centre Paradis-Monticelli, Marseille, France
| |
Collapse
|
5
|
Blackwell K, Gascon P, Krendyukov A, Gattu S, Li Y, Harbeck N. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 2019; 29:244-249. [PMID: 29091995 DOI: 10.1093/annonc/mdx638] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background In 2015, the biosimilar filgrastim EP2006 became the first biosimilar approved by the US Food and Drug Administration for commercial use in the United States, marketed as Zarxio® (Sandoz). This phase III randomised, double-blind registration study in patients with breast cancer receiving (neo)adjuvant myelosuppressive chemotherapy (TAC; docetaxel + doxorubicin + cyclophosphamide) compares reference filgrastim, Neupogen® (Amgen), with two groups receiving alternating treatment with reference and biosimilar every other cycle. Patients and methods A total of 218 patients receiving 5 µg/kg/day filgrastim over six chemotherapy cycles were randomised 1: 1: 1: 1 into four arms. Two arms received only one product, biosimilar or reference (unswitched), and two arms (switched) received alternating treatments every other cycle (biosimilar then reference or vice versa over six cycles). Since the switch occurred from cycle 2 onwards, this analysis compared pooled switched groups to the unswitched reference group for efficacy during cycles 2-6. Safety was also assessed. Non-inferiority in febrile neutropenia (FN) rates between groups for cycles 2-6 was shown if 95% were within a pre-defined margin of - 15%. Results A total of 109 patients switched treatment, and 52 patients received reference in all cycles. Baseline characteristics were similar between groups. The incidence of FN was 0% (reference) versus 3.4% (n = 3, switched) across cycles 2-6, with a difference of - 3.4% (95% confidence interval: -9.65% to 4.96%), showing non-inferiority. Infections occurred in 9.3% (switched) versus 9.9% (reference). Hospitalisation due to FN was low (one patient in cycle 6; switched). Adverse events related to filgrastim were reported in 42.1% (switched) versus 39.2% (reference) (all cycles). Musculoskeletal/connective tissue disorders related to filgrastim occurred in 35.5% (switched) versus 39.2% (reference) (all cycles), including bone pain (30.8% versus 33.3%). No neutralising antibodies were detected. Conclusions There were no clinically meaningful results regarding efficacy, safety or immunogenicity when switching from reference to biosimilar filgrastim/EP2006, or vice versa.
Collapse
Affiliation(s)
- K Blackwell
- Duke Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| | - P Gascon
- Fundacio Clinic, Hospital Clínic de Barcelona, Barcelona, Spain
| | | | - S Gattu
- Hexal AG, Holzkirchen, Germany
| | - Y Li
- Sandoz Inc, Princeton, USA
| | - N Harbeck
- Brustzentrum, Universität München (LMU), Munich, Germany
| |
Collapse
|
6
|
Beylerian M, Sampo M, Gascon P, Stolowy N, Matonti F, Denis D, Hugo J. Multimodal imaging including adaptive optics: A case of a candida chorioretinitis progressing to endogenous endophthalmitis. J Fr Ophtalmol 2019; 42:e127-e129. [PMID: 30824310 DOI: 10.1016/j.jfo.2018.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 06/05/2018] [Accepted: 06/11/2018] [Indexed: 11/16/2022]
Affiliation(s)
- M Beylerian
- Department of ophthalmology, CHU Nord, 13915 Marseille, France.
| | - M Sampo
- Department of ophthalmology, CHU La Timone, 13005 Marseille, France
| | - P Gascon
- Department of ophthalmology, CHU Nord, 13915 Marseille, France
| | - N Stolowy
- Department of ophthalmology, CHU Nord, 13915 Marseille, France
| | - F Matonti
- Department of ophthalmology, CHU Nord, 13915 Marseille, France
| | - D Denis
- Department of ophthalmology, CHU Nord, 13915 Marseille, France
| | - J Hugo
- Department of ophthalmology, CHU La Timone, 13005 Marseille, France
| |
Collapse
|
7
|
Gonzalvez M, Ho Wang Yin G, Gascon P, Denis D, Hoffart L. Clinical and para-clinical description of a novel mutation for Schnyder dystrophy in a French family. J Fr Ophtalmol 2018; 41:920-925. [PMID: 30446344 DOI: 10.1016/j.jfo.2018.03.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 03/21/2018] [Accepted: 03/22/2018] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The objective of this article is to describe the evolution of Schnyder dystrophy in 3 related patients of different ages and to highlight the discovery of a new mutation unidentified until now. CASE REPORT We present a series of 3 cases, all first-degree relatives with no suggestion of consanguinity, of different ages (30, 40 and 59 years) and two distinct generations (mother and children). Slit lamp examination revealed the same lesions in our three patients: an early-onset corneal arcus senilis, central corneal deposits, and a gray stromal haze in the two oldest subjects. The older the patient, the more numerous and dense were these lesions. The various anterior segment OCTs showed an increase in the number of hyperreflective opacities in the anterior stroma and, in the older subject, the appearance of many posterior shadows. Monitoring of pachymetry by Pentacam® showed progressive age-related thickening. All three patients had dyslipidemia treated with statins or diet alone. In our case we proposed treatment only to subject A because of the significant impact on her visual acuity. DISCUSSION Numerous clinical, para-clinical and genetic descriptions of this disease are found in the literature. Schnyder dystrophy is rare but not unheard of and may be discovered fortuitously or in the setting of decreased visual acuity. Genetic analysis of our family revealed a mutation of the UBIAD1 gene not described in the literature. UBIAD1 encodes the protein domain-containing UbiA prenyltransferase 1 which converts vitamin K1 into K2 and is involved in the cholesterol synthesis pathway. In the case of a mutation, it is no longer functional, leading to the accumulation of cholesterol crystals. Given the clinical context and the presence of this variant of the reference sequence in all relatives, its pathogenesis is strongly suspected in our family. The originality of our article is to present the progression of the same pathology in 3 patients with the same mutation at different ages and degrees of severity. This notion of progressive worsening and the need to treat late in the majority of cases are found in literature. CONCLUSION The discovery of a new variant within the UBAID1 gene suggests its pathogenesis in view of the clinical features available to us. The dystrophy is initially asymptomatic before the high number of deposits becomes disabling.
Collapse
Affiliation(s)
- M Gonzalvez
- Aix-Marseille université, 13284 Marseille, France; Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille, France.
| | - G Ho Wang Yin
- Aix-Marseille université, 13284 Marseille, France; Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille, France
| | - P Gascon
- Aix-Marseille université, 13284 Marseille, France; Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille, France
| | - D Denis
- Aix-Marseille université, 13284 Marseille, France; Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille, France
| | - L Hoffart
- Aix-Marseille université, 13284 Marseille, France; Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille, France
| |
Collapse
|
8
|
Beylerian M, Donnadieu B, Beylerian M, Gascon P, Matonti F, Denis D. [Atypical choroidal osteoma: Case report]. J Fr Ophtalmol 2018; 41:e307-e310. [PMID: 30139540 DOI: 10.1016/j.jfo.2017.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 12/08/2017] [Accepted: 12/22/2017] [Indexed: 10/28/2022]
Affiliation(s)
- M Beylerian
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France.
| | - B Donnadieu
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France
| | - M Beylerian
- Service d'ophtalmologie, CHU Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34000 Montpellier, France
| | - P Gascon
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France
| | - F Matonti
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France
| | - D Denis
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France
| |
Collapse
|
9
|
Blackwell K, Gascon P, Jones CM, Nixon A, Krendyukov A, Nakov R, Li Y, Harbeck N. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Ann Oncol 2018. [PMID: 28637287 PMCID: PMC5834021 DOI: 10.1093/annonc/mdx303] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Following the functional and physicochemical characterization of a proposed biosimilar, comparative clinical studies help to confirm biosimilarity by demonstrating similar safety and efficacy to the reference product in a sensitive patient population. Patients and methods LA-EP2006 is a proposed biosimilar that has been developed for pegfilgrastim, a long-acting form of granulocyte colony-stimulating factor for the prevention of neutropenia. The current analysis reports data pooled from two independent, multinational, prospective, randomized, controlled, double-blind phase III studies of similar design comparing the safety and efficacy of reference pegfilgrastim with LA-EP2006 in patients with breast cancer receiving myelotoxic (neo)adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy and requiring granulocyte colony-stimulating factor. Results A total of 624 patients were randomized in the PROTECT-1 and PROTECT-2 studies (NCT01735175; NCT01516736) (LA-EP2006: n = 314; reference: n = 310). Baseline characteristics of patients were well balanced across treatment groups. The primary end point, mean duration of severe neutropenia in the first chemotherapy cycle was similar in both the LA-EP2006 and reference groups (1.05 ± 1.055 days versus 1.01 ± 0.958 days), with a treatment difference of - 0.04 days [95% confidence interval (CI): -0.19 to 0.11] that met the equivalence criteria (the 95% CI were within the defined margin of ±1 day). Secondary end points, such as the nadir of absolute neutrophil count and the incidence of febrile neutropenia, were also similar between LA-EP2006 and reference pegfilgrastim. The safety and tolerability profile of LA-EP2006 was similar to that observed with reference pegfilgrastim, and there were no reports of neutralizing antibodies. Conclusions This pooled analysis confirms, as a part of totality of evidence approach, that the proposed biosimilar pegfilgrastim LA-EP2006 has a comparable efficacy and safety profile to reference pegfilgrastim in patients with breast cancer receiving TAC chemotherapy. Clinical trial numbers NCT01735175 and NCT01516736.
Collapse
Affiliation(s)
- K Blackwell
- Department of Oncology, Duke University, DUMC, Durham, USA
| | - P Gascon
- Medical Oncology Department, Hospital General Vall d'Hebron, Barcelona, Spain
| | | | - A Nixon
- Fowler Family Center for Cancer Care, Jonesboro, USA
| | | | - R Nakov
- Hexal AG, Holzkirchen/Oberhaching, Germany
| | - Y Li
- Sandoz Inc., Princeton, USA
| | - N Harbeck
- Breast Center, Department of Obstetrics and Gynecology, and CCCLMU, University of Munich (LMU), Munich, Germany
| |
Collapse
|
10
|
Nicolau B, García-Morillo M, Rodriguez A, García-Villa A, Cortes K, Calderon C, Beato C, Palomares L, Otero R, Gascon P, Monreal M, Font C. Awareness and understanding of venous thromboembolism in patients with cancer: data on 100 unselected cancer outpatients. Thromb Res 2018. [DOI: 10.1016/j.thromres.2018.02.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
11
|
Aapro M, Krendyukov A, Krivtsova N, Gascon P. Treatment patterns and outcomes in patients with breast cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia: Results from the MONITOR-GCSF study. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30384-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Beylerian M, Gascon P, Beylerian H, Matonti F, Denis D. [Embryotoxon in Axenfeld-Rieger syndrome in an infant]. J Fr Ophtalmol 2017; 41:100-101. [PMID: 29241980 DOI: 10.1016/j.jfo.2017.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 08/17/2017] [Indexed: 11/26/2022]
Affiliation(s)
- M Beylerian
- Service d'ophtalmologie, CHU Hôpital Nord, chemin des Bourrely, 13015 Marseille, France.
| | - P Gascon
- Service d'ophtalmologie, CHU Hôpital Nord, chemin des Bourrely, 13015 Marseille, France
| | - H Beylerian
- Service d'ophtalmologie, CHU Gui-de-Chauliac, Montpellier, France
| | - F Matonti
- Service d'ophtalmologie, CHU Hôpital Nord, chemin des Bourrely, 13015 Marseille, France
| | - D Denis
- Service d'ophtalmologie, CHU Hôpital Nord, chemin des Bourrely, 13015 Marseille, France
| |
Collapse
|
13
|
Varenne F, Mahieu L, Gascon P, Matonti F, Soler V. [Surgical management of serous macular detachment associated with tilted disc syndrome]. J Fr Ophtalmol 2017; 40:e381-e384. [PMID: 29079335 DOI: 10.1016/j.jfo.2016.07.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Revised: 07/28/2016] [Accepted: 07/31/2016] [Indexed: 11/17/2022]
Affiliation(s)
- F Varenne
- Retina Unit, Ophthalmology Department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France
| | - L Mahieu
- Retina Unit, Ophthalmology Department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France
| | - P Gascon
- Hôpital Nord, chemin des Bourrely, 13915 Marseille, France
| | - F Matonti
- Hôpital Nord, chemin des Bourrely, 13915 Marseille, France
| | - V Soler
- Retina Unit, Ophthalmology Department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France; Unité différenciation épithéliale et autoimmunité rhumatoïde, UMR 1056 Inserm, CHU Purpan, place du Dr-Baylac, 31059 Toulouse cedex, France.
| |
Collapse
|
14
|
Aranda E, Camps Herrero C, Khosravi P, Feyjoo M, Anton Torres A, Gascon P, Garcia Foncillas J, Diaz Rubio E, Guillem Porta V, Carrato A, Constenla Figueiras M, Cruz Hernandez J, López R. How do Spanish medical oncologists manage breakthrough pain? A national study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Gascon P, Krendyukov A, Höbel N, Aapro M. Treatment patterns and outcomes in the DLBCL cohort of a study (MONITOR-GCSF) assessing biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Gascon
- Division of Medical Oncology, Department of Hematology-Oncology, Hospital Clínic de Barcelona; University of Barcelona; Barcelona Spain
| | | | | | - M. Aapro
- Institut Multidisciplinaire d'Oncologie; Clinique de Genolier; Genolier Switzerland
| |
Collapse
|
16
|
Comet A, Donnadieu B, Courjaret JC, Gascon P, Denis D, Matonti F. [Brimonidine and acute anterior granulomatous uveitis: A case report and literature review]. J Fr Ophtalmol 2017; 40:e127-e129. [PMID: 28336279 DOI: 10.1016/j.jfo.2016.01.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Revised: 01/06/2016] [Accepted: 01/15/2016] [Indexed: 11/18/2022]
Affiliation(s)
- A Comet
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France.
| | - B Donnadieu
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France
| | - J-C Courjaret
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France
| | - P Gascon
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France
| | - D Denis
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France; CNRS, institut de neurosciences de la Timone (UMR7289), Aix-Marseille université, 13005 Marseille, France
| | - F Matonti
- Service d'ophtalmologie, CHU Nord, chemin des Bourrely, 13015 Marseille, France; CNRS, institut de neurosciences de la Timone (UMR7289), Aix-Marseille université, 13005 Marseille, France
| |
Collapse
|
17
|
Nicolau B, García-Morilla M, Stefi Cortes K, Calderon C, Gascon P, Suarez C, Jara Palomares L, Colomé E, Manazaneda J, Fernandez-Ortega P, Otero R, Monreal M, Font C. P-063: Awareness of venous thromboembolism in patients with cancer: does the gender matter? Thromb Res 2017. [DOI: 10.1016/s0049-3848(17)30161-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Blackwell K, Gascon P, Jones CM, Nixon A, Nakov R, Mo M, Krendyukov A, Nadia H. Abstract P2-11-05: Safety, immunogenicity and efficacy of proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in breast cancer: Pooled analysis of two randomized, double-blind, phase III trials. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-11-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Biosimilars are highly similar to a biological reference product with no clinically meaningful differences in terms of efficacy and safety. Here we present the pooled analysis of two randomized trials (PROTECT1 and 2) comparing the efficacy, safety and immunogenicity of proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim (Neulasta®*).
Methods: Two multinational, independent, prospective, double-blind, phase III studies (EudraCT: 2011-004532-58; 2012-002039-28) enrolled adult chemotherapy-naïve women with breast cancer scheduled to receive ≤6 cycles of (neo)-adjuvant chemotherapy with docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (TAC). Patients were randomized to receive a single 6 mg injection of LA-EP2006 or reference on Day 2 of each cycle. Primary endpoint was duration of severe neutropenia (DSN) (number of consecutive days with ANC <0.5x109/L) in Cycle 1. Equivalence was confirmed if the 95% confidence intervals (CI) for the difference in mean DSN between groups were within a pre-defined margin of ±1 day. Secondary efficacy endpoints included incidences of febrile neutropenia (FN), fever and infections, and depth of ANC nadir and time to ANC recovery (≥2×109/L after the nadir) in Cycle 1. Safety was assessed at each visit with follow-up visits at 4 weeks and 6 months (PROTECT1 only) after last administration of pegfilgrastim. Immunogenicity was assessed before the first pegfilgrastim injection, on Day 15 of cycle 6, and 4 weeks and 6 months (PROTECT1 only).
Results: A total of 624 patients were randomized (LA-EP2006: n=314; reference: n=310). Baseline demographics were well balanced (mean age: LA-EP2006: 49.3 years, reference: 49.8; median duration (months) since initial diagnosis: LA-EP2006: 1.33 [0.1−76.0], reference: 1.35 [0.2−11.2]; ECOG status 0: LA-EP2006: 78%, reference: 75%). Mean DSN difference in Cycle 1 was -0.04 days (95% CI: -0.19, 0.11), showing statistical equivalence. FN was reported in 5.7% of patients with LA-EP2006 vs. 8.4% with reference in Cycle 1 (all cycles: 8.0% vs. 10.3%). Across all cycles, frequency of fever (LA-EP2006: 18.5%; reference: 19.7%) and infections (LA-EP2006: 15.6%; reference: 18.1%) were similar in both groups. Mean ANC time courses were almost superimposable in the two groups, with similar time and depth of ANC nadir and median time to ANC recovery was 2 days in both groups in Cycle 1. Treatment-emergent adverse events (TEAEs) were similar across groups (LA-EP2006: 92%; reference: 89%), and TEAEs with a suspected relationship to pegfilgrastim were reported in 22.6% of patients with LA-EP2006 and 21.3% with reference across all cycles, with the most frequent being musculoskeletal and connective tissue disorders (LA-EP2006: 10.2%; reference: 9.7%). Serious TEAEs were reported in 14.3% (LA-EP2006) vs. 17.1% (reference) across all cycles. No neutralizing or clinically relevant anti-pegfilgrastim antibodies were identified.
Conclusions: LA-EP2006 demonstrated similar clinical efficacy and safety to reference pegfilgrastim in patients with breast cancer receiving myelotoxic chemotherapy.
*Neulasta® is a registered trademark of Amgen Inc.
Citation Format: Blackwell K, Gascon P, Jones CM, Nixon A, Nakov R, Mo M, Krendyukov A, Nadia H. Safety, immunogenicity and efficacy of proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in breast cancer: Pooled analysis of two randomized, double-blind, phase III trials [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-11-05.
Collapse
Affiliation(s)
- K Blackwell
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| | - P Gascon
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| | - CM Jones
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| | - A Nixon
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| | - R Nakov
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| | - M Mo
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| | - A Krendyukov
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| | - H Nadia
- Duke Cancer Institute, Durham, NC; Fundacio Clinic, Barcelona, Spain; The Jones Clinic, Memphis, TN; Fowler Family Center for Cancer Care, Jonesboro, AR; Sandoz Inc/ Hexal AG, Holzkirchen, Germany; Sandoz Inc, Holzkirchen, Germany; Brustzentrum der Universität München (LMU), Munich, Germany
| |
Collapse
|
19
|
Harbeck N, Gascon P, Jones C, Nixon A, Krendyukov A, Nakov R, Mo M, Blackwell K. LBA2 Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer receiving myelotoxic chemotherapy: Pooled subgroup analysis of two randomized trials. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw637.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Harbeck N, Gascon P, Jones C, Nixon A, Krendyukov A, Nakov R, Mo M, Blackwell K. LBA2 Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer receiving myelotoxic chemotherapy: Pooled subgroup analysis of two randomized trials. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00747-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
21
|
Alfon J, Vidal L, Gaba L, Victoria I, Gil M, Laquente B, Brunet M, Colom H, Ramis J, Perez-Montoyo H, Cortal M, Gomez-Ferreria M, Muñoz P, Erazo T, Lizcano J, Domenech C, Gascon P. Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Bragado P, Alonso R, Mancino M, Fernandez-Nogueira P, Fuster G, Gascon P. Neuropilin 2 regulates lung disseminated tumor cells escape from dormancy and progression into metastasis. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61265-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Sampo M, Soler V, Gascon P, Ho Wang Yin G, Hoffart L, Denis D, Matonti F. Traitement par éplérénone dans la choriorétinite séreuse centrale chronique. J Fr Ophtalmol 2016; 39:535-42. [DOI: 10.1016/j.jfo.2016.01.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Revised: 01/18/2016] [Accepted: 01/25/2016] [Indexed: 10/21/2022]
|
24
|
Aya F, Fernandez-Martinez A, Gaba L, Victoria I, Tosca M, Pineda E, Gascon P, Prat A, Arance A. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clin Transl Oncol 2016; 19:119-124. [PMID: 27147251 DOI: 10.1007/s12094-016-1514-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Accepted: 04/18/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE Immunotherapy (IT) agents and BRAF inhibitors (BRAFi) are effective treatments for patients with advanced BRAF-mutant melanoma although the optimal sequence remains to be elucidated. The aim of this study was to compare the outcomes of two different cohorts of patients treated with BRAFi first, then IT or the reverse sequence. PATIENTS AND METHODS This is a retrospective study on two groups of patients: a cohort was treated first with BRAFi followed by immunotherapy (BRAFi-IT) and the other cohort with the reverse sequence (IT-BRAFi). Baseline characteristics and clinical outcomes were compared between the two cohorts. RESULTS A total of 25 patients were included in the study. Sixteen patients were given BRAFi-IT sequence and nine received IT-BRAFi sequence. No differences were observed in the characteristics of patients prior to each treatment between cohorts. Objective response rate (ORR) achieved by BRAFi were not different among groups. ORR achieved by IT was higher when administered after BRAFi (43.8 vs 0 %). Survival rates at 1-2 years were similar in both cohorts and median overall survival was not different for BRAFi-IT and IT-BRAFi (log rank test p = 0.97). CONCLUSIONS No differences were observed in OS between the two cohorts. These results support the indistinct use of IT or BRAFi as initial treatment in patients with metastatic BRAF-mutant melanoma, although higher rate of response to IT was observed when administered after BRAFi. Prospective randomized clinical trials are needed on this issue.
Collapse
Affiliation(s)
- F Aya
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. .,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - A Fernandez-Martinez
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - L Gaba
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - I Victoria
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - M Tosca
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - E Pineda
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - P Gascon
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| | - A Prat
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - A Arance
- Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| |
Collapse
|
25
|
Donnadieu B, Amouyal F, Comet A, Gascon P, Courjaret JC, Denis D, Matonti F. [Retinal arterial macroaneurysms with intraretinal exudates]. J Fr Ophtalmol 2015; 39:107-8. [PMID: 26614262 DOI: 10.1016/j.jfo.2015.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 02/13/2015] [Accepted: 02/20/2015] [Indexed: 11/25/2022]
Affiliation(s)
- B Donnadieu
- Service d'ophtalmologie, centre hospitalier universitaire Nord, chemin des Bourrelys, 13015 Marseille, France.
| | - F Amouyal
- Service d'ophtalmologie, centre hospitalier universitaire Nord, chemin des Bourrelys, 13015 Marseille, France
| | - A Comet
- Service d'ophtalmologie, centre hospitalier universitaire Nord, chemin des Bourrelys, 13015 Marseille, France
| | - P Gascon
- Service d'ophtalmologie, centre hospitalier universitaire Nord, chemin des Bourrelys, 13015 Marseille, France
| | - J-C Courjaret
- Service d'ophtalmologie, centre hospitalier universitaire Nord, chemin des Bourrelys, 13015 Marseille, France
| | - D Denis
- Service d'ophtalmologie, centre hospitalier universitaire Nord, chemin des Bourrelys, 13015 Marseille, France
| | - F Matonti
- Service d'ophtalmologie, centre hospitalier universitaire Nord, chemin des Bourrelys, 13015 Marseille, France
| |
Collapse
|
26
|
Donnadieu B, Gascon P, Amouyal F, Aziz A, Matonti F, Denis D. Cataracte congénitale unilatérale associée à une persistance du canal de Cloquet. J Fr Ophtalmol 2015; 38:895. [DOI: 10.1016/j.jfo.2015.01.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 01/15/2015] [Indexed: 11/16/2022]
|
27
|
Gascon P, Marc C, Guigou S. [Spontaneous bilateral dislocation of the crystalline lens in the case of a patient with homocystinuria, with anterior chamber OCT showing endothelial damage]. J Fr Ophtalmol 2015; 38:e173-5. [PMID: 26138529 DOI: 10.1016/j.jfo.2014.06.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2014] [Revised: 05/18/2014] [Accepted: 06/16/2014] [Indexed: 11/29/2022]
Affiliation(s)
- P Gascon
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France.
| | - C Marc
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France
| | - S Guigou
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France
| |
Collapse
|
28
|
Gascon P, Sisiroi M, Soare S, Pestre V, Daniel L, Guigou S. [A case of TINU syndrome with lymphocytic alveolitis in a 15-year-old girl]. J Fr Ophtalmol 2015; 38:e91-3. [PMID: 25891771 DOI: 10.1016/j.jfo.2014.06.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2014] [Accepted: 06/03/2014] [Indexed: 11/18/2022]
Affiliation(s)
- P Gascon
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France.
| | - M Sisiroi
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France
| | - S Soare
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France
| | - V Pestre
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France
| | - L Daniel
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France
| | - S Guigou
- Centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France
| |
Collapse
|
29
|
Marín-Aguilera M, Reig O, Carrera G, Garcia LG, Jiménez N, Pereira V, Gascon P, Mellado B. Micrornas Expression in Blood Associated with Taxanes Response and Overall Survival in Metastatic Castration-Resistant Prostate Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Escobar Y, Cajaraville G, Virizuela J, Alvarez Alvarez R, Muñoz Martín A, Olariaga O, Muros B, Lecumberri Biurrun M, Feliu J, Martinez Del Prado P, Cruz Hernandez J, Martínez Bautista M, Lopez R, Blasco A, Gascon P, Calvo V, Luna Fra P, Montalar J, Del Barrio P, Tornamira M. Incidence of Chemotherapy-Induced Nausea and Vomiting with Moderately Emetogenic Chemotherapy: Advice Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Mancino M, Fernandez-Nogueira P, Enreig E, Ametller E, Gascon P, Almendro V. 579: Subtype specific expression of HRH1 contributes to increased chemoresistance of breast cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50514-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Reig O, Marín-Aguilera M, Lozano J, Gonzalez B, Mallofré C, Campayo M, Gascon P, Mellado B. 693: Intrinsic resistance to sunitinib in clear cell renal cell carcinoma: A gene expression analysis. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50612-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Gascon P, Tesch H, Verpoort K, Rosati M, Salesi N, Barker H, Agrawal S, Muenzberg M, Turner M. Use of Biosimilar G-CSF for Prevention of Chemotherapy-Induced Neutropenia: Pooled Analysis of Clinical Usage Studies. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34101-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
34
|
Grau J, Caballero M, Vilalta A, Victoria I, Reig O, Gascon P, Carrera C, Malvehy J. Electrochemotherapy (ECT) with Bleomycin as a Palliative Treatment of Regional Relapse in Head and Neck Cancer (H&NC) Patients (PTS). a Pilot Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33602-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
35
|
Aapro M, Gascon P, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Muenzberg M, Denhaerynck K, Abraham I, Macdonald K. Biosimilar Filgrastim Initiation in Patients Enrolled in the Monitor G-CSF Observational Study Relative to EORTC Guidelines. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34099-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
36
|
Gascon P, Casas A, Muñoz J, De Castro J, Alberola V, Cucala M, Barón F. Anaemia-Related Fatigue in Patients with Solid Tumours: a Multicenter, Observational and Prospective Study (Pacs Study). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34108-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
37
|
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012; 23:1986-1992. [PMID: 22396444 DOI: 10.1093/annonc/mds021] [Citation(s) in RCA: 210] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND While guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) are widely available, clinical uptake of guidelines remains low. Our objective was to evaluate the effect of guideline-consistent CINV prophylaxis (GCCP) on patient outcomes. PATIENTS AND METHODS This prospective, observational multicenter study enrolled chemotherapy-naive adults initiating single-day highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer. Patients completed 6-day daily diaries beginning with cycle 1 for up to three chemotherapy cycles. The primary study end point, complete response (no emesis and no use of rescue therapy) during 120 h after cycle 1 chemotherapy, was compared between GCCP and guideline-inconsistent CINV prophylaxis (GICP) cohorts using multivariate logistic regression, adjusting for potential confounding factors. RESULTS In cycle 1 (N=991), use of GCCP was 55% and 46% during acute and delayed phases, respectively, and 29 % for the overall study period (acute plus delayed phases). Complete response was recorded by 172/287 (59.9%) and 357/704 (50.7%) patients in GCCP and GICP cohorts, respectively (P=0.008). The adjusted odds ratio for complete response was 1.43 (95% confidence interval 1.04-1.97; P=0.027) for patients receiving GCCP versus GICP. CONCLUSION GCCP reduces the incidence of CINV after single-day HEC and MEC.
Collapse
Affiliation(s)
- M Aapro
- Medical Oncology and Radiation, IMO Clinique de Genolier, Genolier, Switzerland.
| | - A Molassiotis
- School of Nursing Midwifery and Social Work, University of Manchester, Manchester, UK
| | - M Dicato
- Hematology-Oncology, Luxembourg Medical Center, Luxembourg, Luxembourg
| | - I Peláez
- Hospital de Cabuenes, Gijón, Spain
| | | | - D Pastorelli
- Oncologic Institute of the Veneto, Padova, Italy
| | - L Ma
- Global Health Outcomes, Merck Sharp & Dohme Corp., Whitehouse Station, USA
| | - T Burke
- Global Health Outcomes, Merck Sharp & Dohme Corp., Whitehouse Station, USA
| | - A Gu
- Global Health Outcomes, Merck Sharp & Dohme Corp., Whitehouse Station, USA
| | - P Gascon
- Institute of Hematology and Medical Oncology, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - F Roila
- Medical Oncology, Santa Maria Hospital, Terni, Italy
| |
Collapse
|
38
|
Mancino M, Saez C, Pastor E, Fuster G, Ametller E, Gascon P, Almendro V. 229 Identification of DNA Co-segregation During Cell Division in Breast Cancer Cell Lines. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70924-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Recio SG, Fuster G, Nogueira PF, Arroyo EP, Tella CM, Ametller E, Park S, Fernandez P, Gascon P, Almendro V. 806 Transmodulation of ErbB Receptors by Proinflammatory Mediator Substance P. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71439-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Fernandez-Nogueira P, Rye I, Fuster G, Solvang H, Pares M, García-Recio S, Gascon P, Borresen-Dale A, Russnes H, Almendro V. 423 Acquisition of Resistance to Anti-Her2 Therapies Promotes a Different Microenvironment Crosstalk Capability. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71105-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Reig O, Font C, Victoria I, Villalta J, Farrús B, Reverter J, Tàssies D, Tuca A, Gascon P. Thrombotic superior vena cava syndrome in cancer patients: data from a single center cohort of 340 consecutive patients. Thromb Res 2012. [DOI: 10.1016/s0049-3848(12)70104-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
42
|
Font C, Farrús B, Vidal L, Caralt T, Visa L, Mellado B, Tàssies D, Monteagudo J, Reverter J, Gascon P. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol 2011; 22:2101-2106. [DOI: 10.1093/annonc/mdq720] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
43
|
Gaba L, Ortega V, Font C, Farrús B, Tàssies D, Reverter JC, Gascon P. Venous thromboembolism in outpatients with cancer receiving chemotherapy for solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Ortega V, Gaba L, Font C, Reig O, Victoria I, Visa L, Pineda E, Oleaga L, Gascon P. Central nervous system venous thrombosis in cancer: Frequency and clinical characteristics in a prospective observational study of 339 patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Visa L, Grau JJ, Caballero M, Pineda E, Ortega V, Gaba L, Gascon P. Analysis of patient age and adjuvant chemotherapy (ACh) as predictor of survival in patients (pts) with resected gastric adenocarcinoma (RGA). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Campayo M, Navarro A, Vinolas N, Tejero R, Munoz C, Diaz T, Marrades RM, Cabanas ML, Gimferrer JM, Ramirez J, Gascon P, Monzo M. A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding site of KRT81 and time to recurrence (TTR) in patients (p) with surgically resected non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Tagliapietra A, Gaba L, Castelo-Branco C, Torrents A, Gascon P, Vidal Boixader L. Prevalence and risk factors for sexual dysfunction in gynecologic tumors survivors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Vidal-Pla A, Pérez-Torras S, Miquel R, Navarro S, Gascon P, Maurel J, Carbo N, Mazo A. Targeted therapy to EGFR and HER2 combined with gemcitabine in a novel human pancreatic orthotopic model. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Campayo M, Font C, Farrús B, Reverter JC, Tàssies D, Reguart N, Vinolas N, Gascon P. Venous thromboembolism (VTE) in patients with lung cancer (LC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19565] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Canon JR, Vansteenkiste JF, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken JB, Legg JC, Bridges KR, Pujol B. An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus ≥ 10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|